ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy
Bio Pharma Dive
JUNE 6, 2022
The biotech's highly anticipated breast cancer data were upstaged by a rival, while presentations from Roche, J&J and Adicet Bio highlighted emerging alternatives to CAR-T treatment.
Let's personalize your content